Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Shilpa Medicare Limited

NSE: SHILPAMEDPharmaceuticalsASM stage 1

Share price

₹1,025.30

-4.28% close of 8 Oct 2026

Market cap ₹20,506 CrP/E 72.2

Business score

How strong the business is, in one number. The parts behind it are in Pro.

59

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹20,506 Cr

P/E ratio

72.2

P/B ratio

7.8

ROCE

10.9%

ROE

9.0%

Dividend yield

0.1%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹1,073.7052-week low ₹267.00

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 27.9% over the past year, and 16.1% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 15.7% to 28.4% over the last four years.

Whether it grew faster than its sector

It grew 16.1% a year against a sector median of 13.1% — 3.0 percentage points faster.

Room to re-rate, or risk of de-rating

At 72.2× earnings it costs 3.0× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 64.9×, the 59th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.7 times its growth rate, on earnings growth of 107%.

Profit growthPrice per ₹1 profitPer 1% growth
Shilpa Medicare Limited — this one107%/yr72.2×—
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 85 of 130 on returns, 37 of 127 on growth, 27 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 10.9% on capital, ahead of 35% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

No — Over the last five years it made ₹896 crore of cash from the business but spent ₹1316 crore on plant and equipment, ₹420 crore more than it made; the gap was from shareholders — borrowings did not rise. And the profit is real: of every 100 rupees it reported over 12 years, about 127 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 77 days for its cash to waiting 51 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Best-ever quarter, sales up 45% and profit doubled with help from a one-off tax credit

Announced 5 Aug 2026 · Consolidated · Unaudited

Revenue

₹466 Cr

Revenue vs last year

+45.1%

Revenue vs last quarter

+6.6%

Net profit

₹101 Cr

Profit vs last year

+114.6%

Profit vs last quarter

-6.6%

Net margin

21.7%

EPS

₹5.16

Earnings call transcript · 5 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹20,506 Cr
Prev close
₹1,025.30
52w High
₹1,095
52w Low
₹260
Enterprise value
₹21,121 Cr
Beta
1.1
Price CAGR 1y
200.0%
Price CAGR 3y
86.0%
Price CAGR 5y
29.0%
Price CAGR 10y
14.0%

Ratios

Return on assets
6.6%
PEG ratio
0.7
P/E ratio
72.2
P/B ratio
7.8
EV / EBITDA
44.2
Industry P/E
38.0
ROCE
10.9%
ROCE 5y average
6.2%
ROE
9.0%
Debt / Equity
0.3
Interest coverage
6.0
Dividend yield
0.1%
ROE 3y average
5.0%
ROE last year
9.0%

Annual P&L

Annual revenue
₹1,535 Cr
Annual profit
₹243 Cr
Operating margin
28.0%
Net profit margin
15.8%
EBITDA margin
28.3%
Sales growth 3y
13.6%
Sales growth 5y
11.3%
Profit growth 3y
107.0%
Profit growth 5y
17.0%
EPS
₹12.4
Sales growth TTM
28.0%
Profit growth TTM
117.0%
Dividend payout
5.0%

Quarter P&L

Sales latest quarter
₹466 Cr
Profit latest quarter
₹101 Cr
YoY quarterly sales growth
44.9%
YoY quarterly profit growth
114.9%
OPM latest quarter
29.3%

Balance Sheet

Book Value
₹130
Face Value
₹1.0
Total debt
₹660 Cr
Total cash
₹45 Cr
Borrowings
₹660 Cr
Reserves / Equity
128.6

Cash Flow

Operating cash flow
₹342 Cr
Free cash flow
-₹15 Cr
FCF yield
-0.4%
Net cash flow
₹17 Cr

Shareholding

Promoter holding
40.1%
FII holding
12.1%
DII holding
8.3%
Public holding
39.5%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,750.3533.24,19,9680.902,901.26.015,299.910.520.5
Divi's Lab.9,427.9084.02,50,2810.31902.065.53,080.027.822.0
Torrent Pharma.4,630.0079.01,76,1100.81566.05.84,921.054.915.2
Zydus Lifesci.1,113.5022.91,11,0720.09990.2-35.18,017.022.021.1
Laurus Labs2,027.00100.21,09,5210.10362.1125.52,026.329.117.8
Cipla1,297.5029.31,04,8210.98785.6-39.27,119.32.315.5
Mankind Pharma2,380.0046.098,3050.04574.129.64,030.612.913.5
Shilpa Medicare1,030.5570.920,1560.06100.9115.1465.844.910.9
Median416.7034.32,1130.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales260313287292293344319331321370410437466
Expenses214255222222222258239252231262296317330
Material Cost85115128101128145
Change in Inventories13-40-29257.44-18
Purchases of Stock-in-Trade6.644.167.367.146.988.45
Employee Cost7182838387100
Other Expenses796873798995
Operating Profit465865707086817991108114120136
OPM %18192324242525242829282729
Other Income22291052-2162-13459
Exceptional items (within Other Income)-2800-13430
Interest18232624242612141916111412
Depreciation27282727272829292930303135
Profit before tax3914282937421550646112098
Tax %6483671251512455322710-3
Net Profit1252414183215474445108101
EPS in Rs0.070.090.261.410.720.921.620.742.402.252.285.515.16
Diluted EPS in Rs1.484.792.252.365.515.16

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales6147197797897339088991,1411,0461,1521,2861,5391,683
Expenses4855666146345856887189409479079621,1001,204
Material Cost350471
Change in Inventories38-36
Purchases of Stock-in-Trade2226
Employee Cost293335
Other Expenses266309
Operating Profit12915316515514821918120299239319435479
OPM %2121212020242018921252828
Other Income551522331790211715-83943
Exceptional items (within Other Income)-2829
Interest47334522415992765952
Depreciation212931374244548096108113120126
Profit before tax108122146137136188195102-3854122295344
Tax %3319292519182541-19413618
Net Profit739910410311015514661-313278243297
EPS in Rs4.786.736.716.456.889.579.063.49-1.871.8441215
Diluted EPS in Rs8.0412
Dividend Payout %644576616-0-0125

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
8%
5 years
11%
3 years
14%
TTM
28%

Compounded profit growth

10 years
8%
5 years
17%
3 years
107%
TTM
117%

Stock price CAGR

10 years
14%
5 years
29%
3 years
86%
1 year
200%

Return on equity

10 years
6%
5 years
4%
3 years
5%
Last year
9%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital8888888998.689.7820
Reserves5396399791,0771,1891,3211,4711,8141,7751,8002,3532,572
Borrowings189221241191194390846683798937588660
Other Liabilities169194244223218270308370323347360455
Minority Interest-8.53
Total Liabilities9051,0621,4721,4991,6101,9892,6322,8762,9043,0933,3113,706
Fixed Assets3165804925345586501,1111,3421,3681,3851,4181,593
CWIP22295141210429666541506655719822884
Investments6653253140210213443403558
Other Assets3013345876156216629599938389501,0371,170
Total Assets9051,0621,4721,4991,6101,9892,6322,8762,9043,0933,3113,706

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity69129374514712447105180137132342
Cash from Investing Activity-196-106-257-10-196-290-404-286-232-171-198-339
Cash from Financing Activity136-20313-61101764368346476314
Net Cash Flow9393-26-391079-98-713-317
Free Cash Flow-7412-79-92-151-220-302-226-46-48-84-15

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days4843801021019988124113125126123
Inventory Days147161187194266298427338280309309291
Days Payable851011101061151229113912515693113
Cash Conversion Cycle111104157189253275425323268278342301
Working Capital Days3327799898687277-13488051
ROCE %181614109128615811

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Sep 2026
Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters505044444444444440404040
FIIs8.525.639.089.599.9011111111111112
DIIs0.061.657.618.188.277.557.467.678.348.588.058.26
Public414339383837373741404039
No. of Shareholders43,63046,04641,07242,78449,03450,10848,63652,06553,79953,41060,92687,477

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +177.9% (₹369.00 → ₹1,025.30)Brick size ₹48.97 (fixed)Bricks 17
₹250₹500₹750₹1,025Jan '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹1,025.30 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

615inr_cr

2026-03-31

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

News

News and filings about Shilpa Medicare Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • medicines / bulk drugs / others
  • packing material
  • raw material / chemicals (KSMs, intermediates, solvents)

Buys drug ingredients from

  • Shilpa Pharma Lifesciences Limited

Sells to

  • Amneal Pharmaceuticals · BORUZU / bortezomib ready-to-use injection for the US market
  • Unicycive Therapeutics · Oxylanthanum carbonate (OLC) tablets; development, manufacturing, supply & CMC services

Buys from

  • Beardsell Limited · clean-room panels — List of Customers logo wall (shilpabio logo, Shilpa Biologicals is Shi…

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE790G01031

Plants

  • API Unit I - DTA Raichur / Shilpa Pharma Lifesciences · Raichur, Karnataka
  • API Unit II - 100% Export-Oriented Unit Raichur / Shilpa Pharma Lifesciences · Raichur, Karnataka
  • Biologics Unit - Shilpa Biologicals · Dharwad, Karnataka
  • Kadechur Fermentation Facility / Shilpa Biocare · Kadechur, Karnataka
  • Manufacturing Unit - Bengaluru / Dabaspet · Dobaspet / Bengaluru Rural, Karnataka
  • Quality Control and Bioanalytical Division - Unit VII Nacharam · Hyderabad, Telangana
  • SEZ Unit - Jadcherla · Jadcherla, Telangana
  • Therapeutics Unit - Hyderabad / Shilpa Therapeutics · Hyderabad, Telangana

News impact

Big market events that reach Shilpa Medicare Limited, and how the effect spreads.

Who it hits first

  • Sterile-injectable makers (Gland, Aurobindo, Lupin, Caplin, Shilpa) face new licensing layer
  • Small job-work sterile units face consolidation pressure
  • CDSCO capacity becomes the approval bottleneck

Who may gain

  • Large compliant players gain share as small units exit
  • Testing and validation service firms gain business

Along the supply chain

Downstream

Hospitals pay slightly more for assured-quality injectables.

Upstream

API and vial suppliers see steadier demand from compliant makers.

Where demand moves

Business

Plants undergo central audits; documentation and QA headcount rise; approvals add months to greenfield timelines.

Capital

Money favours large, audit-ready pharma over small sterile job-workers.

How it spreads across sectors

Healthcare

injectable compliance cost rises; consolidation favours leaders

When it plays out

Immediate

Injectable stocks soften on cost headlines.

Medium term

Cleaner industry commands better US/EU pricing power.

Short term

Watch draft rules, timelines and grandfathering clauses.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

4 Sep 2026unspecified₹0.6
3 Oct 2025bonus₹0
17 Sep 2025unspecified₹1
19 Sep 2022unspecified₹1.1
20 Sep 2021unspecified₹1.1
16 Mar 2020interim₹1.1
12 Sep 2019unspecified₹1
1 Mar 2018interim₹0.7

Splits, bonuses & buybacks

  • daily-prices repair: 9 rows from NSE's archive (replace 1, delete 1, insert 7), 2016-10-30..2026-02-01 (docs/flat_day_repair.md)1× · 30 Oct 2016

Bulk & block deals

DateWhoBought / soldSharesPrice
6 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDSELL10,77,507₹760.04
6 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDBUY10,77,507₹759.36
5 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDSELL11,03,058₹723.16
5 Aug 2026MICROCURVES TRADING PRIVATE LIMITEDBUY11,03,058₹722.79

Insider trades

DisclosedWhoTypeSharesValue ₹ Cr
29 Sep 2026Alpesh Maheshkumar Dalal · KMPSELL4,0000.42

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.